Jason Y Zhang

US Patent:

20050009843, Jan 13, 2005

Filed:

Apr 24, 2002

Appl. No.:

10/475091

Inventors:

Kiyoshi Nakayama - Tokyo, JP
Masami Ohtsuka - Tokyo, JP
Haruko Kawato - Tokyo, JP
Ryo Okumura - Tokyo, JP
Kazuki Hoshino - Tokyo, JP
William Watkins - Waltham MA, US
Jason Zhang - Waltham MA, US
Monica Palme - Waltham MA, US
Aesop Cho - Waltham MA, US

International Classification:

A61K031/519

US Classification:

514259410

Abstract:

A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, Rand Rrepresent hydrogen atom, a halogen atom, hydroxyl group or the like, Wrepresents —CH═CH—, —CHO—, —CHCH— or the like; Rrepresents hydrogen atom, a halogen atom, hydroxyl group or an amino group; Rrepresents hydrogen atom, a group of —OZR(Zrepresents an alkylene group, a fluorine-substituted alkylene group or a single bond, and Rrepresents a cyclic alkyl group, an aryl group or the like); Wrepresents a single bond or —C(R)═C(R)—(Rand Rrepresent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but Wand Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

US Patent:

20120223321, Sep 6, 2012

Filed:

Mar 22, 2011

Appl. No.:

13/053556

Inventors:

Heny Lin - Irvine CA, US
Jason Zhang - Monterey Park CA, US
Alberto Guerra - Palos Verdes Estates CA, US

Assignee:

INTERNATIONAL RECTIFIER CORPORATION - El Segundo CA

International Classification:

H01L 29/12

US Classification:

257 76, 257E29068

Abstract:

One exemplary disclosed embodiment comprises a three-terminal stacked-die package including a field effect transistor (FET), such as a silicon FET, stacked atop a III-nitride transistor, such that a drain of the FET resides on and is electrically coupled to a source of the III-nitride transistor. A first terminal of the package is coupled to a gate of the FET, a second terminal of the package is coupled to a drain of the III-nitride transistor. A third terminal of the package is coupled to a source of the FET. In this manner, devices such as cascoded switches may be packaged in a stacked-die form, resulting in reduced parasitic inductance and resistance, improved thermal dissipation, smaller form factor, and lower manufacturing cost compared to conventional packages.

US Patent:

20120223322, Sep 6, 2012

Filed:

Mar 22, 2011

Appl. No.:

13/053646

Inventors:

Heny Lin - Irvine CA, US
Jason Zhang - Monterey Park CA, US
Alberto Guerra - Palos Verdes Estates CA, US

Assignee:

INTERNATIONAL RECTIFIER CORPORATION - El Segundo CA

International Classification:

H01L 29/20

US Classification:

257 76, 257E29089

Abstract:

One exemplary disclosed embodiment comprises a two-terminal stacked-die package including a diode, such as a silicon diode, stacked atop a III-nitride transistor, such that a cathode of the diode resides on and is electrically coupled to a source of the III-nitride transistor. A first terminal of the package is coupled to a drain of the III-nitride transistor, and a second terminal of the package is coupled to an anode of the diode. In this manner, devices such as cascoded rectifiers may be packaged in a stacked-die form, resulting in reduced parasitic inductance and resistance, improved thermal dissipation, smaller form factor, and lower manufacturing cost compared to conventional packages.

US Patent:

20210032620, Feb 4, 2021

Filed:

Aug 7, 2018

Appl. No.:

16/636902

Inventors:

- Singapore, SG
Zhong Zhong - Hingham MA, US
Naoki Iwamoto - Brighton MA, US
Jason Jingxin Zhang - Walpole MA, US
Jean-Cosme Dodart - Boston MA, US
Yuanjing Liu - Arlington MA, US
Pachamuthu Kandasamy - Belmont MA, US
Sethumadhavan Divakaramenon - Lexington MA, US
Genliang Lu - Winchester MA, US
Subramanian Marappan - Acton MA, US

International Classification:

C12N 15/11

Abstract:

Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in treatment of C9orf72-related disorders.

US Patent:

20200362337, Nov 19, 2020

Filed:

Aug 7, 2018

Appl. No.:

16/636900

Inventors:

- Singapore, SG
Yuanjing Liu - Arlington MA, US
Chandra Vargeese - Schwenksville PA, US
Zhong Zhong - Hingham MA, US
Naoki Iwamoto - Brighton MA, US
Jason Jingxin Zhang - Walpole MA, US
Pachamuthu Kandasamy - Belmont MA, US
Sethumadhavan Divakaramenon - Lexington MA, US
Genliang Lu - Winchester MA, US
Subramanian Marappan - Acton MA, US

International Classification:

C12N 15/113

Abstract:

Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in treatment of C9orf72-related disorders.

US Patent:

20200190515, Jun 18, 2020

Filed:

Jun 1, 2018

Appl. No.:

16/618001

Inventors:

- Singapore, SG
- New York NY, US
David Charles Donnell Butler - Medford MA, US
Subramanian Marappan - Acton MA, US
Genliang Lu - Winchester MA, US
Jason Jingxin Zhang - Walpole MA, US
Vinod Vathipadiekal - Stoneham MA, US
Luciano Henrique Apponi - Chelsea MA, US
Hanna Maria Wisniewska - Providence RI, US
Xiayun Cheng - Old Saybrook CT, US
Young Jin Cho - Belmont MA, US

International Classification:

C12N 15/113
A61K 45/06
A61K 47/54
A61K 47/55

Abstract:

Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown.

US Patent:

20200157545, May 21, 2020

Filed:

Jun 1, 2018

Appl. No.:

16/618010

Inventors:

Chandra VARGEESE - Cambridge MA, US
Naoki IWAMOTO - Cambridge MA, US
David Charles Donnell BUTLER - Cambridge MA, US
Subramanian MARAPPAN - Cambridge MA, US
Genliang LU - Cambridge MA, US
Jason Jingxin ZHANG - Cambridge MA, US
Vinod VATHIPADIEKAL - Cambridge MA, US
Luciano Henrique APPONI - Cambridge MA, US
- Singapore, SG

Assignee:

WAVE LIFE SCIENCES LTD. - Singapore

International Classification:

C12N 15/113
A61K 31/712

Abstract:

Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown.

US Patent:

20190390197, Dec 26, 2019

Filed:

Oct 6, 2017

Appl. No.:

16/087577

Inventors:

- Singapore, SG
Sethumadhavan Divakaramenon - Lexington MA, US
Christopher J. Francis - Arlington MA, US
Naoki Iwamoto - Brighton MA, US
Genliang Lu - Winchester MA, US
Subramanian Marappan - Acton MA, US
Chandra Vargeese - Schwenksville PA, US
Gregory L. Verdine - Boston MA, US
Hailin Yang - West Roxbury MA, US
Jason Jingxin Zhang - Walpole MA, US

International Classification:

C12N 15/113
A61P 25/14
A61P 21/00
A61K 48/00
A61K 31/7125

Abstract:

Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.